TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04642365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7296682
Description: RO7296682 will be administered as per the schedules specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7296682
Description: RO7296682 will be administered as per the schedules specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7296682
Description: RO7296682 will be administered as per the schedules specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered as per the schedules specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered as per the schedules specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered as per the schedules specified in the respective arms.
Study: NCT04995549

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cutiscan® CS 100
Description: Repeated measures on healthy volunteers skin (forearm) are performed using Cutiscan® CS 100 device
Study: NCT06156241

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cell
Description: Stem cells derived from human cord tissue.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cell
Description: Stem cells derived from human cord tissue.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cell
Description: Stem cells derived from human cord tissue.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cell
Description: Stem cells derived from human cord tissue.
Study: NCT06040853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid intravenous administration
Description: Participants will be given 15mg/kg tranexamic acid before the incision in ten minutes, 100 mg/h will continue until the end of the surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Participant was given intravenous 100 ml saline
Study: NCT05313737

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Automated message
Description: Automated message via phone call (audiocare)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Opt-out scheduling
Description: Scheduling via non-automated phone call
Study: NCT05699564

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early biomarker-based cardiological assessment
Description: We will perform cardiac biomarker testing with NT-proBNP and hs-cTnT measurements on emergency department admission in all participants, regardless of randomization status. The results will be provided in the patient's EHR, regardless of randomization status. For patients randomized to the intervention group, we will provide a note in the patient's EHR that includes assessment of probability that myocardial injury or dysfunction are the underlying pathophysiology responsible for tachypnea, as evaluated by the cardiac biomarker algorithm of the study. We will inform on general recommendations for work up and treatment.
Study: NCT05417087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine Hemihydrobromide Orally Disintegrating Tablets
Description: Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20 mg equivalent to 20 mg of Vortioxetine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine Hemihydrobromide Orally Disintegrating Tablets
Description: Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20 mg equivalent to 20 mg of Vortioxetine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine Hydrobromide Tablets
Description: Vortioxetine Hydrobromide Tablets 20mg
Study: NCT05244733

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Engage (S-ENGAGE)
Description: S-ENGAGE uses the process of action planning to foster sustained behavior change. Action planning involves: 1) select a goal; 2) develop ideas to meet this goal; 3) choose one or more of these ideas; 4) identify concrete steps to implement the goal (i.e., form an action plan); 5) identify and address barriers if needed.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: The Healthy Lifestyles Education Program
Description: The healthy lifestyles education program is a self-guided psychoeducational program, including a notebook containing evidence-based educational material on mental health, physical activity, and information on community resources.
Study: NCT05526339

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygenation combined with nasopharyngeal airway
Description: The patients receive an oxygen flow of 30 L/min for preoxygenation with a high-flow oxygenation device before losing of conscious. At the time of the abolition of the eyelash reflex, the gas flow was increased to 60 L/min with an inspired oxygen fraction 100% and the nasopharyngeal airway was placed.
Study: NCT05126537

Intervention type: OTHER
Intervention: no intervention
Description: prospective and observational study with no intervention

Intervention type: OTHER
Intervention: no intervention
Description: prospective and observational study with no intervention
Study: NCT05526339

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Regular nasal cannula combined with nasopharyngeal airway
Description: The patients receive an oxygen flow of 6 L/min for preoxygenation with a regular nasal cannula until the end of procedure. At the time of abolition of the eyelash reflex, the nasopharyngeal airway was placed.
Study: NCT05852236

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assigned Interventions
Description: Pressure ulcer care package application.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assigned Interventions
Description: Pressure ulcer care package application.
Study: NCT05969340

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: ultra-high-resolution CT-scan
Description: Use of ultra-high-resolution CT-scan to detect otoconia in the posterior canal BPPV

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ultra-high-resolution CT-scan
Description: Use of ultra-high-resolution CT-scan to detect otoconia in the posterior canal BPPV
Study: NCT05750550

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instrument Assisted Soft Tissue Mobilization
Description: With the IASTM device, application will be made over the skin to the triceps surae muscle and plantar fascia for 15 minutes. The application will be made in the prone position. Massage oil will be used to reduce tissue friction before the application.
Study: NCT05407779

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-180, dose 1
Description: anti-TRBV9 monoclonal antibody single infusion at dose 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-180, dose 2
Description: anti-TRBV9 monoclonal antibody, single infusion at dose 2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-180, dose 3
Description: anti-TRBV9 monoclonal antibody, single infusion at dose 3

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-180, dose 4
Description: anti-TRBV9 monoclonal antibody, single infusion at dose 4

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-180, dose 5
Description: anti-TRBV9 monoclonal antibody, single infusion at dose 5

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-180, dose 6
Description: anti-TRBV9 monoclonal antibody, single infusion at dose 6

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-180, dose 6
Description: anti-TRBV9 monoclonal antibody, single infusion at dose 6

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-180, dose 7
Description: anti-TRBV9 monoclonal antibody, single infusion at dose 7

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-180, dose 7
Description: anti-TRBV9 monoclonal antibody, single infusion at dose 7
Study: NCT06330337

Intervention type: DRUG
Group type: OTHER
Intervention: Temozolomide（TMZ） injection or oral administration
Description: Oral administration of TMZ150-200mg/m2/ day, continuous use for 5 days, discontinued for 23 days, for a treatment cycle, a total of 6 cycles.

Intervention type: DRUG
Group type: OTHER
Intervention: Temozolomide（TMZ） injection or oral administration
Description: Oral administration of TMZ150-200mg/m2/ day, continuous use for 5 days, discontinued for 23 days, for a treatment cycle, a total of 6 cycles.

Intervention type: DRUG
Group type: OTHER
Intervention: Albumin-Bound Paclitaxel(ABX) intravenous drip
Description: ABX was administered intravenously at a dose of 110mg/m2 on days 1 and 8 of a 28-day treatment cycle

Intervention type: DEVICE
Group type: OTHER
Intervention: Specific mode electroacupuncture stimulation(SMES) intervention
Description: Patients take supine position. After skin disinfection with 75% ethanol routine disinfection, the stainless needle (size 0.25mm×40mm, Hua Tuo brand, Suzhou Medical Supplies Company Ltd in Jiangsu, China) will be inserted in GV20（Baihui) and the stainless needle(size 0.25mm×25mm, described above) will be inserted in GV26 (Shuigou), acupoints will be stimulated manually until patients feel soreness, distension or heaviness (the reaction of De Qi). Then, the needles are stimulated by using an acupuncture point nerve stimulator (HANS-200, Nanjing Jinsheng, Ltd., China) with a frequency of 2/100 Hz and an intensity of 3 mA for 40 min (a homemade relay cycled power to the electrode for 6 sec on and 6 sec off).The 28-day treatment cycle was followed by simultaneous intervention with ABX on days 1 and 8.
Study: NCT05096416

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The three-dimensional (3D) printed hemodialysis vascular model
Description: The three-dimensional (3D) printed hemodialysis vascular model will be used as a guide map to cannulate the patients for hemodialysis and to minimize the risk of vascular access complications
Study: NCT05439408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib ASD 100 mg
Description: XS004 Dasatinib Amorphous Solid Dispersion Film-Coated Tablet, 100 mg Test Formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib ASD 100 mg
Description: XS004 Dasatinib Amorphous Solid Dispersion Film-Coated Tablet, 100 mg Test Formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib ASD 100 mg
Description: XS004 Dasatinib Amorphous Solid Dispersion Film-Coated Tablet, 100 mg Test Formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib ASD 100 mg
Description: XS004 Dasatinib Amorphous Solid Dispersion Film-Coated Tablet, 100 mg Test Formulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dasatinib 140 MG [Sprycel]
Description: SPRYCEL® (dasatinib) 140 mg Film-Coated Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dasatinib 140 MG [Sprycel]
Description: SPRYCEL® (dasatinib) 140 mg Film-Coated Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dasatinib 140 MG [Sprycel]
Description: SPRYCEL® (dasatinib) 140 mg Film-Coated Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dasatinib 140 MG [Sprycel]
Description: SPRYCEL® (dasatinib) 140 mg Film-Coated Tablets
Study: NCT06176638

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RRF4H Combination Intervention
Description: MFG: is a family strengthening model where children and their parents sit together in groups of 8 to 10 families to discuss important issues. MFG approach provides a social support mechanism and strengthens family relationships by allowing families to share common experiences as well as effective strategies for addressing difficult issues; and focuses on reducing stigma and normalizing common experiences.~TAHC: This is a peer-led program that allows younger students to talk with peers about important issues that they face, gain role models, and identify positive social norms from older peers. It provides age-appropriate lessons and is delivered in a structured fashion. The curriculum consists of sixteen 50-minute lessons spread out over two academic years. Topics delivered in the curriculum include substance use, positive outlook on life, forming a positive self-concept, decision making and problem solving, coping with depression, bullying and social media.
Study: NCT05945251

Intervention type: OTHER
Intervention: Internet-delivered cognitive behavioral therapy
Description: Ten weekly modules for children and ten weekly modules for parents. Exposure-based cognitive behavioral therapy delivered online with asynchronous support via text messages from psychologists.
Study: NCT06077032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: garlic extract (15%) solution
Description: •Group 1: will apply Vaseline over the normal skin surrounding the lesion(s) then a cotton soaked with garlic extract (15%) solution will be applied under occlusion with a plastic tape for one hour and then washed by tap water daily for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical chlorhexidine (2%) solution
Description: •Group 2: will apply Vaseline over the normal skin surrounding the lesion(s) then a cotton soaked with topical chlorhexidine (2%) solution will be applied under occlusion with a plastic tape for one hour and then washed by tap water daily for 6 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: •Group 3: (control) will use normal saline 0.9% as a placebo (they will be treated later on after completion of the study using any of the standard therapies for non-genital warts).
Study: NCT05665907

Intervention type: OTHER
Intervention: Questionnaire BRIEF (Behavioral Rating Inventory of Executive Function)
Description: Questionnaire BRIEF (Behavioral Rating Inventory of Executive Function)

Intervention type: OTHER
Intervention: Questionnaire BRIEF (Behavioral Rating Inventory of Executive Function)
Description: Questionnaire BRIEF (Behavioral Rating Inventory of Executive Function)
Study: NCT05279820

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Partial pulpotomy
Description: Partial pulp tissue amputation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Full Pulpotomy
Description: Full Pulpotomy
Study: NCT05367843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRIME-2-CoV_Beta
Description: Intramuscular (IM) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRIME-2-CoV_Beta
Description: Intramuscular (IM) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRIME-2-CoV_Beta
Description: Intramuscular (IM) injection
Study: NCT05126537

Intervention type: OTHER
Intervention: no intervention
Description: prospective and observational study with no intervention
Study: NCT05933343

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ethibond suture
Description: An Ethibond™ 1 suture will be placed as a drainage seton for complex anal fistula

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vessel loop
Description: A vessel loop will be placed as a drainage seton for complex anal fistula
Study: NCT06069635

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fatigue protocol (repeated sprint ability)
Description: The test performed on an outdoor field (artificial grass carpet) in the form of 6 repetitions of maximal 2× 15 m shuttle sprints interspersed with 20 seconds of passive recovery , Before the RSA protocol, all players perform a brief standardized warm-up (approximately 20 minutes long), in 1at submaximal speed (followed by 40 seconds of passive recovery The fatigue index (FI) used to characterize the RSA performance was calculated in terms of percentage decrement score At the end of the RSA protocol , usually the time elapsed between the end of the last sprint and the beginning of the measurements was no more than 20 seconds, to avoid masking effects related to progressive recovery from fatigue.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator: Control group
Description: approximately 20 minutes long), which consisted of : 6 minutes of incremental running from 60% to 80% of maximal aerobic speed; 6 minutes of dynamic flexibility exercises; 2 minutes of forward, backward, and lateral jogging and high-knee and ''butt-kick'' runs; 2 minutes of shuttle sprints (5 m in 1 direction and 5 m in the opposite direction, repeated for 2 minutes) at submaximal speed (followed by 40 seconds of passive recovery); and 2 minutes of RSA protocol simulation at submaximal speed (2 repetitions), again followed by 40 seconds of passive recovery. take apenalty of water and rest
Study: NCT05781464

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional chest physiotherapy
Description: Postural drainage: the patient is positioned in postural drainage so that gravity had the maximum effect on the lung segment that needed to be drained, all lung zones are emphasised in positional initiatives for babies.~Percussion is the rhythmic striking of the chest wall with cupped hands for 1 to 2 minutes at a time.~Vibration is performed by placing fingers on the chest wall over the segment being drained and isometrically contracting the forearm and hand muscles to produce a vibratory motion.~Vibration is accomplished either through manual vibratory motion of the therapist's fingers on the infant's chest wall or through the use of a mechanical vibrator ( Foreo vibrator).

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Traditional chest physiotherapy
Description: Postural drainage: the patient is positioned in postural drainage so that gravity had the maximum effect on the lung segment that needed to be drained, all lung zones are emphasised in positional initiatives for babies.~Percussion is the rhythmic striking of the chest wall with cupped hands for 1 to 2 minutes at a time.~Vibration is performed by placing fingers on the chest wall over the segment being drained and isometrically contracting the forearm and hand muscles to produce a vibratory motion.~Vibration is accomplished either through manual vibratory motion of the therapist's fingers on the infant's chest wall or through the use of a mechanical vibrator ( Foreo vibrator).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged slow expiration technique
Description: The therapist places one hand on the thorax below the suprasternal notch and the other hand over the upper abdomen while the neonate is supine. Both hands will have hypothenar contact with the thorax and abdomen. At the end of the expiratory phase, the therapist places a compression force with both hands. Compression at the end of expiration with hypothenar eminence is kept for 2 or 3 breathing cycles. This technique is repeated several times, with a rest time between applications of about 5 or 10 spontaneous breaths.
Study: NCT06043973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: almonertinib
Description: The specific treatment regimen is as follows: Non-squamous NSCLC: almonertinib (110 mg/d) plus anlotinib (12mg/d) is started on the first day of each treatment cycle and administered every three weeks until disease progression or intolerable toxicity. Anlotinib was given for two weeks, followed by one week off.
Study: NCT05691647

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chronotherapy
Description: Chronotherapy involves three different interventions. Sleep deprivation/wake therapy will be conducted for 34 hours. To assist wake and to ensure that the participants adhere to the sleep deprivation, they will be admitted to a one-night stay at the inpatient ward that is connected to the outpatient clinic at Nidaros DPS. Upon discharge, participants are encouraged to adhere to the sleep schedule which presents the sleep-wake phase advancement and later stabilization of the sleep-wake phase. Light therapy is provided for half an hour every day from day four in the study. In addition to the chronotherapeutic interventions, the participants will receive treatment as usual (TAU) with their assigned therapist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Participants allocated to receive TAU alone, will receive standard treatment for a depressive episode in the outpatient clinic. This study will not give restrictions or guidelines on how this treatment should be performed. The TAU-group will receive the treatment the responsible therapist considers and evaluate best fitting in the situation. Typical interventions administered in therapy for a depressive episode includes medication, cognitive behavioral therapy, and other psychotherapies.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Participants allocated to receive TAU alone, will receive standard treatment for a depressive episode in the outpatient clinic. This study will not give restrictions or guidelines on how this treatment should be performed. The TAU-group will receive the treatment the responsible therapist considers and evaluate best fitting in the situation. Typical interventions administered in therapy for a depressive episode includes medication, cognitive behavioral therapy, and other psychotherapies.
Study: NCT05405101

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thermal ablation of aldosterone producing adenoma.
Description: On the left side, Radiofrequency ablation of aldosterone producing adenoma(s) will be undertaken via the stomach (endoscopically), under transgastric ultrasound guidance.~On the right side, either Radiofrequency or Microwave Ablation of aldosterone producing adenoma(s) will be performed via a percutaneous approach, under CT guidance.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Unilateral adrenalectomy
Description: Unilateral total adrenalectomy for aldosterone producing adenoma. This will be laparoscopic in the vast majority of patients, with open conversion if surgically indicated (unlikely in \>1-2 patients)
Study: NCT06423131

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TCRαβ Depleted haploidentical HCT
Description: Use the CliniMACS TCRα/β deplete from the mobilized peripheral blood stem cells of haploidentical donor in children
Study: NCT04792632

Intervention type: DEVICE
Intervention: Veye Lung nodules
Description: Veye Lung Nodules
Study: NCT05541549

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CE-VST01-JC
Description: CE-VST01-JC at a dose of 1 × 10\^8 cells administered as an intravenous (IV) infusion every 28 days for 4 total infusions

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: CE-VST01-JC
Description: CE-VST01-JC at a dose of 1 × 10\^8 cells administered as an intravenous (IV) infusion every 28 days for 4 total infusions
Study: NCT06315699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clemastine Fumarate Tablets
Description: The dose was administered 2mg once daily in a double-blind random crossover method

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: fructose
Description: The dose was administered 2mg once daily in a double-blind random crossover method